In an era of health reform, diagnostic technologies that focus on prevention and test the viability of expensive treatment options are becoming increasingly valuable to health providers, payers, and patients. Historically, investment in this sector has not seen the vigor demonstrated with medical devices or biotech innovations. However, in today’s environment, diagnostics are becoming attractive opportunities for companies looking for collaborations or acquisitions as well as investors looking for cutting-edge technologies, all creating a robust industry on the brink of breaking through to the mainstream.
In this presentation, panelists will:
- Provide insight on the diagnostic industry on a local and national level
- Discuss key elements that are reviewed when assessing start-up opportunities
- Discuss where opportunities exist for maximizing profits
- Provide new strategies for raising funds in this dynamic marketplace
Panelists:
Stephen DiPalma, Chief Financial Officer, Envivo Pharmaceuticals
Ronald S. Eppen, Partner, Foley & Lardner LLP
Mitchell Sanders, CEO and Founder, ECI Biotech
Related Insights
December 23, 2025
Energy Current
FERC Opens New Paths for Co-Located Loads in PJM: What Data Center and Power Generation Developers Need to Know
Key Takeaways FERC has ordered PJM to overhaul its tariff framework for co-located generation and large loads, finding existing rules…
December 23, 2025
Foley Viewpoints
The Rush to Exit: PE Firms Pick Up the Pace in 2025
Key Points: PE firms are moving to sell portfolio companies on an accelerated timeline in 2025 after years of much longer hold…
December 23, 2025
Tariff & International Trade Resource
Grandma Got Audited by a Reindeer
So…it’s Christmastime. Which can only mean it’s time for the Christmas tradition that everyone has been waiting for all year…our annual holiday compliance parody article!